Bioavailability of bovine lactoferrin after a novel microencapsulation process and its effect on inflammatory markers and the gut microbiome.

Dr Olivia Wright0 个研究点目标入组 12 人开始时间: 2016年8月9日最近更新: 2020年1月13日

试验速览

暂无简介。

•Healthy body weight (body mass index [BMI] 18.5-24.9 kg/m2), not overweight or obese
•- Available to participate for the required timeframe of the study (10 weeks)
•- Not anaemic (i.e. Haemoglobin greater than or equal to 150 plus or minus 20g/L; Haematocrit greater than or equal to 0.45 plus or minus 0.05; red blood cell count greater than or equal to 5.0 plus or minus 0.5 x 1012/L)
•- Non smoker

•- Any allergy or intolerance to dairy products
•- BMI <18.5 or >24.9 kg/m2
•- Current consumption of lactoferrin-fortified products or lactoferrin supplements
•- Inability to provide informed consent due to diminished understanding or comprehension, or a language other than English spoken and an interpreter unavailable
•-Anaemic (i.e. Haemoglobin greater than or equal to 150 plus or minus 20g/L; Haematocrit greater than or equal to 0.45 plus or minus 0.05; red blood cell count greater than or equal to 5.0 plus or minus 0.5 x 1012/L)
•-Taking any form of recreational drug
•-Taking immunosuppressives (i.e. corticosteroids such as prednisone; monoclonal antibodies including basiliximab, daclizumab and muromonab; cyclosporine or azathioprine; tacrolimus; sirolimus; mycophenolate mofetil; other cytotoxic drugs, e.g. methotrexate, chlorambucil) or any other immunomodulating drugs or analogues (i.e. levamisole, immune globulin, thymic factors, cytokines, thalidomide, lenalidomide, Revlimid, Actimid, pomalidomide and apremilast).
•-Current viral infection (without reference to serology)
•-Consuming >2 standard drinks on any day (i.e. alcohol consumption beyond the national guidelines)
•-Smokers, including those in the process of quitting – i.e. using e-cigs and nicotine patches

发起方

Dr Olivia Wright